Does Blue Cross Blue Shield of Illinois Cover Trulicity?

What Is Trulicity and Why Do Insurers Scrutinize It?

Trulicity (dulaglutide) is a once-weekly injectable GLP-1 receptor agonist approved by the FDA in September 2014 for glycemic control in adults with type 2 diabetes, with a subsequent indication for reducing major adverse cardiovascular events (MACE) in adults with type 2 diabetes who have established cardiovascular disease or multiple cardiovascular risk factors. 1 Because Trulicity carries a branded price exceeding $900 per month without insurance, payers including BCBSIL apply formulary management tools, prior authorization requirements, and step-therapy protocols before approving coverage.

How GLP-1 Receptor Agonists Work

Dulaglutide binds GLP-1 receptors in the pancreas, gut, and brain. It stimulates glucose-dependent insulin secretion, suppresses glucagon release, slows gastric emptying, and reduces appetite. 2 The glucose-dependent mechanism means it carries a low intrinsic risk of hypoglycemia as monotherapy, which differentiates it from sulfonylureas on most formularies.

The REWIND Trial: Why Cardiologists and Payers Both Pay Attention

The REWIND trial (N=9,901, median follow-up 5.4 years) showed dulaglutide 1.5 mg weekly reduced the composite MACE endpoint (nonfatal MI, nonfatal stroke, or cardiovascular death) by 12% versus placebo (HR 0.88; 95% CI 0.79 to 0.99; P<0.026). 3 The trial included a broad population, with approximately 46% of participants having no prior cardiovascular disease at baseline. This breadth of evidence supports use in primary prevention contexts, which affects how payers justify coverage beyond just glycemic management.

FDA Label Scope and Off-Label Use

The FDA label does not currently approve dulaglutide for weight loss as a standalone indication. That distinction matters for BCBSIL coverage decisions. Plans routinely cover Trulicity for type 2 diabetes management but may deny claims coded solely for obesity without a concurrent diabetes diagnosis. The American Diabetes Association's Standards of Care in Diabetes 2024 recommend GLP-1 receptor agonists with proven cardiovascular benefit for patients with type 2 diabetes and established or high-risk cardiovascular disease, independent of baseline HbA1c. 4

How BCBSIL Formularies Are Structured

Blue Cross Blue Shield of Illinois operates multiple plan lines: PPO, HMO, Blue Advantage HMO, Blue Choice, Medicare Advantage (BlueChoice Preferred PPO), and Medicaid managed care (Blue Cross Community Health Plans). Each product line maintains a separate formulary document, updated annually each January, with mid-year changes possible for newly approved drugs or generic entries.

Tier Placement for Dulaglutide

Across most BCBSIL commercial plans, dulaglutide sits at Tier 3 (preferred brand) or Tier 4 (non-preferred brand). The exact tier depends on negotiated rebate agreements between Eli Lilly and BCBSIL, which shift annually. Members should check the current formulary through the BCBSIL member portal at bcbsil.com or call the member services number on the back of their insurance card to confirm the current tier for the plan year in question.

Tier placement directly affects cost-sharing:

• Tier 3 (preferred brand): Typical copay or coinsurance of $50 to $100 per 28-day supply after deductible
• Tier 4 (non-preferred brand): Typical coinsurance of 30% to 50% of negotiated price after deductible
• Tier 5 (specialty): Some BCBSIL plans place injectables on a specialty tier with separate cost-sharing rules and mandatory specialty pharmacy dispensing

Step Therapy Requirements

Most BCBSIL commercial plans require step therapy before approving a branded GLP-1 agonist. Step therapy typically requires documented use of metformin for at least 90 days, or documentation of a contraindication or intolerance. Some plans additionally require a trial of a sulfonylurea or SGLT-2 inhibitor before authorizing a GLP-1 agonist. The ADA's Standards of Care recommend against step therapy that delays GLP-1 agonist initiation when cardiovascular or renal benefit is the primary indication, 4 but payer policies do not always align with clinical guidelines.

Prior Authorization: What BCBSIL Typically Requires

Prior authorization (PA) is required for Trulicity on virtually all BCBSIL commercial plans. Your prescribing clinician submits the PA request, not the pharmacy. Understanding the criteria in advance allows the prescriber to prepare the chart documentation before the PA is submitted, which reduces the rate of initial denials.

Standard PA Criteria for Dulaglutide

BCBSIL's PA criteria for GLP-1 receptor agonists typically include all of the following:

1. Confirmed type 2 diabetes mellitus diagnosis (ICD-10 code E11.x)
2. HbA1c above individualized target despite current therapy (most plans require HbA1c above 7.0% or 7.5%)
3. Documented trial of metformin at maximally tolerated dose for at least 90 days, or documented contraindication or intolerance
4. Prescriber is an appropriate specialty (primary care, endocrinology, or cardiology for cardiovascular indication)
5. No concurrent prescription for another GLP-1 receptor agonist (e.g., semaglutide, liraglutide)

For members with established cardiovascular disease, documenting the cardiovascular indication explicitly, citing the REWIND trial or ADA cardiovascular guidelines, 4 can support approval even when glycemic targets are near goal.

The PA Approval Timeline

Most BCBSIL PA decisions are issued within 3 to 5 business days for standard reviews. Urgent PA requests, submitted when a prescriber certifies that the standard timeline could seriously jeopardize the patient's health, must be resolved within 72 hours under Illinois Department of Insurance regulations. If BCBSIL does not respond within the applicable timeframe, the PA is considered approved by default under state law.

What to Do After a PA Denial

Denials typically cite failure to meet step-therapy criteria or insufficient clinical documentation. The appeals process has two levels:

• Level 1 Internal Appeal: Submitted by the member or prescriber within 180 days of the denial notice. BCBSIL must respond within 30 days for standard appeals.
• External Independent Review: If the internal appeal is denied, Illinois law entitles members to an independent external review by an independent review organization (IRO), typically resolved within 45 days.

The Endocrine Society's clinical practice guidelines note that GLP-1 receptor agonists are first-line adjuncts to metformin when cardiovascular risk reduction is a treatment goal, 5 which provides guideline-based language for appeal letters.

Trulicity Coverage on Specific BCBSIL Plan Types

Commercial PPO and HMO Plans

For employer-sponsored and individual-market PPO and HMO plans, Trulicity is generally covered with PA. The deductible phase is the most expensive period. Before the deductible is met, members may pay the full negotiated price (often $400 to $600 per fill), not just a copay.

Medicare Advantage Plans (BlueChoice Preferred PPO)

BCBSIL Medicare Advantage formularies are governed by CMS Part D rules. Dulaglutide is covered under Medicare Part D, not Part B, because it is a self-administered injectable. Under the Inflation Reduction Act's drug pricing provisions, which took effect in 2024, Medicare Part D out-of-pocket costs are capped at $2,000 annually starting in 2025. 6 This cap meaningfully limits maximum annual exposure for Medicare Advantage members taking Trulicity.

GLP-1 receptor agonists are specifically excluded from Medicare coverage when prescribed solely for weight loss. CMS does not cover weight-loss drugs under Part D unless a separate indication (type 2 diabetes) is documented. 6

Medicaid Managed Care (Blue Cross Community Health Plans)

For Illinois Medicaid members enrolled in Blue Cross Community Health Plans, Trulicity coverage follows the Illinois Medicaid preferred drug list (PDL). Illinois Medicaid has historically preferred metformin, sulfonylureas, and certain SGLT-2 inhibitors before GLP-1 agonists. PA is required. Medicaid PA denials are subject to the same appeal rights as commercial plans and can also be escalated to the Illinois Department of Healthcare and Family Services.

How Much Will Trulicity Cost With BCBSIL Coverage?

Cost varies across plan phases. The table below provides estimates based on typical BCBSIL commercial plan structures. These are estimates, not guarantees, and members should verify with BCBSIL directly.

| Plan Phase | Tier 3 Estimate | Tier 4 Estimate | |---|---|---| | Before deductible met | $400 to $600 per fill (full negotiated price) | $400 to $600 per fill | | After deductible, before out-of-pocket max | $50 to $100 copay or 30% coinsurance | 40% to 50% coinsurance | | After out-of-pocket max met | $0 (plan pays 100%) | $0 (plan pays 100%) |

The Eli Lilly Savings Card

For commercially insured patients (not Medicare or Medicaid), Eli Lilly offers a Trulicity Savings Card that can reduce cost-sharing to as low as $25 per month, with a maximum annual benefit of $2,400. 7 The savings card does not apply to government-funded coverage, including Medicare Part D, Medicaid, or CHIP. Patients who cycle on and off commercial coverage should note that savings card eligibility resets annually.

GoodRx and Specialty Pharmacy Alternatives

GoodRx and similar discount programs may offer lower cash prices at specific pharmacies (often $700 to $800 per fill at select pharmacies), but using a GoodRx price means not using insurance. This can affect whether the fill counts toward the annual deductible or out-of-pocket maximum. For patients in the deductible phase early in the year who plan to hit their maximum later, using insurance, even at higher cost initially, may be the better long-term strategy.

Clinical Context: Is Trulicity the Right GLP-1 for You?

Multiple GLP-1 receptor agonists are available, and formulary placement differs across plans. Semaglutide (Ozempic, once-weekly injection; Rybelsus, oral) and liraglutide (Victoza) are direct competitors on the BCBSIL formulary. In some plan years, one may have a lower tier and therefore lower cost-sharing than dulaglutide.

Comparative Efficacy Data

In the SUSTAIN-7 trial (N=1,201), once-weekly semaglutide 1.0 mg reduced HbA1c by 1.9% versus 1.4% for dulaglutide 1.5 mg (P<0.0001 for superiority), with greater weight loss as well (6.5 kg vs. 3.0 kg). 8 However, clinical superiority in a trial does not automatically translate to the best formulary access or lowest out-of-pocket cost on a specific plan. A medication that a patient can reliably afford and consistently inject produces better real-world glycemic outcomes than a clinically superior drug abandoned due to cost.

ADA Guidance on GLP-1 Selection

The ADA's 2024 Standards of Care state: "For patients with type 2 diabetes and established cardiovascular disease or indicators of high cardiovascular risk, a GLP-1 receptor agonist with proven cardiovascular benefit is recommended as part of the glucose-lowering regimen." 4 Both dulaglutide (REWIND) and semaglutide (SUSTAIN-6, PIONEER-6) have trials supporting this recommendation, giving prescribers flexibility to choose based on formulary access and individual patient factors.

When to Consider Switching Drugs for Formulary Reasons

If Trulicity is denied or cost-prohibitive on your BCBSIL plan, your clinician may prescribe a formulary-preferred alternative. Switching from dulaglutide to once-weekly semaglutide involves a transition period of one to two weeks at minimum; both drugs occupy the same receptor class with similar mechanisms. The Endocrine Society notes that GLP-1 receptor agonists share a class mechanism, and switching within class is clinically acceptable when driven by cost or access considerations. 5

Strategies to Maximize Your Chance of Coverage Approval

The following framework reflects HealthRX clinical team experience across GLP-1 prior authorization submissions and is designed to reduce denial rates for BCBSIL Trulicity requests.

Step 1. Confirm formulary status before prescribing. Call BCBSIL member services or use the online formulary tool to verify the current tier and PA requirements for dulaglutide on the member's specific plan. Formularies update January 1; a plan that covered Trulicity at Tier 3 in 2024 may move it to Tier 4 in 2025.

Step 2. Document the clinical indication completely. The chart note supporting the PA should include: type 2 diabetes diagnosis with ICD-10 code, most recent HbA1c with date, current medication list, documentation of metformin trial or reason for contraindication, and any cardiovascular history or risk factors.

Step 3. Cite guideline support in the PA letter. Reference the ADA Standards of Care 2024 4 and the REWIND trial 3 explicitly. Payer medical reviewers respond to named guidelines and named trials.

Step 4. Request urgent review when clinically appropriate. If the patient is newly diagnosed with elevated HbA1c above 9% and has cardiovascular disease, the prescriber can certify that delay constitutes a health risk, triggering the 72-hour urgent review pathway.

Step 5. Appeal immediately on denial. Submit a Level 1 appeal with supplemental documentation, including peer-reviewed literature and the treating clinician's letter of medical necessity, within 30 days of denial for the fastest resolution timeline.

Step 6. Use the savings card as a bridge. While the appeal is pending, commercially insured patients can use the Eli Lilly savings card to obtain Trulicity at reduced cost without waiting for the appeal outcome. 7

What If BCBSIL Won't Cover Trulicity at All?

Some plans, particularly certain self-funded employer plans that opt out of state insurance mandates, may exclude branded GLP-1 agonists from the formulary entirely. In that case, options include:

• Formulary alternative: Ask whether liraglutide (Victoza) or oral semaglutide (Rybelsus) is on the formulary at a lower tier.
• Exception request: File a formulary exception, which requests non-formulary coverage based on medical necessity. BCBSIL is required to have a formulary exception process under ACA provisions.
• Patient assistance program: Eli Lilly's Insulin Value Program and broader patient assistance may cover Trulicity at no cost for patients below income thresholds. Contact Lilly Cares Foundation directly.
• 340B pricing: Patients receiving care at a 340B-covered entity (qualifying federally qualified health centers, Ryan White clinics, and certain hospital outpatient departments) may access dulaglutide at 340B-discounted pricing.

The FDA's guidance on biosimilar and generic pathways notes that no interchangeable biosimilar for dulaglutide has been approved as of the date of this article, 1 meaning there is no lower-cost generic option currently available.

Monitoring and Safety Considerations Once Coverage Is Secured

Obtaining coverage is only the first step. Once Trulicity is approved and dispensed, clinical monitoring requirements apply. The FDA label for dulaglutide carries a boxed warning for thyroid C-cell tumors observed in rodent studies; the drug is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2. 1

Common Adverse Effects and Adherence

GI adverse effects (nausea, diarrhea, vomiting) affect approximately 12% to 21% of patients on dulaglutide 1.5 mg in the AWARD trial program and are most pronounced in the first four to eight weeks. 9 Initiating at the 0.75 mg dose for four weeks before escalating to 1.5 mg reduces GI burden and improves adherence. Real-world adherence data from a 2021 analysis of pharmacy claims found that 12-month persistence on once-weekly GLP-1 agonists ranged from 42% to 58%, with cost burden identified as the primary driver of discontinuation. 10 This underscores why resolving the coverage and cost question before prescribing directly affects clinical outcomes.

HbA1c and Weight Monitoring Schedule

Standard monitoring while on dulaglutide includes HbA1c every three months until target is achieved, then every six months. Weight should be recorded at each visit. Renal function (eGFR and creatinine) should be checked at baseline and annually, as dose adjustment guidance exists for severe renal impairment. The ADA recommends that clinicians reassess cardiovascular and renal benefit annually and document the ongoing indication in the chart, which also supports continued PA renewals. 4